ara-290 vs bpc-157 16mg ARA 290, a Nonerythropoietic Peptide

Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy

Severe intracranial (superior sagittal sinus) hypertension, portal and caval hypertension, and aortal hypotension were attenuated/eliminated

People with Crohns disease need to watch for signs of B12 deficiency

Basic properties and clinical applications." Expert Opinion on Biological Therapy